[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Assassi et al., 2024 - Google Patents

Systemic sclerosis (scleroderma)

Assassi et al., 2024

Document ID
17523448846749574133
Author
Assassi S
Varga J
Publication year
Publication venue
The Rose and Mackay Textbook of Autoimmune Diseases

External Links

Snippet

Systemic sclerosis (SSc), historically called scleroderma, is an autoimmune connective tissue disease with complex and poorly understood pathogenesis. SSc has protean clinical manifestations, follows a chronic and commonly progressive course, and is associated with …
Continue reading at www.sciencedirect.com (other versions)

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Hybridisation probes
    • C12Q1/6883Hybridisation probes for diseases caused by alterations of genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers

Similar Documents

Publication Publication Date Title
Shah et al. My approach to the treatment of scleroderma
Yang et al. Long-term sequelae of Stevens-Johnson syndrome/toxic epidermal necrolysis
Ha et al. Lung involvements in rheumatic diseases: update on the epidemiology, pathogenesis, clinical features, and treatment
Richardson et al. Esophageal dilatation and interstitial lung disease in systemic sclerosis: a cross-sectional study
Mayes et al. Systemic sclerosis
US10011883B2 (en) Causative agents and diagnostic methods relating to rheumatoid arthritis
Gemignani et al. Lactulose breath test to assess oro-cecal transit delay and estimate esophageal dysmotility in scleroderma patients
Halleran et al. Does Hirschsprung-associated enterocolitis differ in children with and without down syndrome?
Plastiras et al. Determinants of pulmonary arterial hypertension in scleroderma
Liu et al. Prevalence and clinical importance of gastroesophageal reflux in Chinese patients with systemic sclerosis
Didona et al. The polymorphous spectrum of dermatomyositis: classic features, newly described skin lesions, and rare variants
Assassi et al. Systemic Sclerosis (Scleroderma)
Stoilov et al. Therapeutic effect of oral CF101 in patients with rheumatoid arthritis: a randomized, double-blind, placebo-controlled phase II study
Ikenouchi et al. Geriatric nutrition risk index predicts prolonged post-stroke dysphagia in acute ischemic stroke
Varga et al. Scleroderma–Systemic Sclerosis
JP4174203B2 (en) How to determine the susceptibility to bone damage
RU2722459C1 (en) Method for determining progression of joint destruction in a patient suffering rheumatoid arthritis background of 5-year therapy of basic anti-inflammatory drugs or basic anti-inflammatory drugs in combination with genetically engineered biological preparations and / or psychopharmacotherapy and accompanying anxiety-depressive disorder
Denton et al. Raynaud’s Phenomenon and Scleroderma
Kapur et al. Exacerbation of asthma by isotretinoin
Man et al. Systemic Sclerosis
Derrett-Smith et al. Systemic sclerosis: clinical features and management
Esmaeili et al. New insights of anti-depressant therapy in the management of ulcerative colitis (UC)
Lambova et al. Systemic sclerosis
Hesselstrand et al. FRI0496 An Open-Label Study to Evaluate Biomarkers and Safety in Systemic Sclerosis (SSC) Patients Treated with Paquinimod (ABR-215757)
Fischer SYSTEMIC SCLEROSIS